ALGS: Aligos Therapeutics, Inc. Common Stock Company Profile & Statistics

About

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

Info & Links

CEO

Lawrence M. Blatt

Headquarters

ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Aligos Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

29.38M

Enterprise Value

-7.57M

Enterprise Value/EBITDA(ttm)

0.09

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

12.47

Price to Book(mrq)

1.38

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1283.19%

Profit Margin(ttm)

-4409.22%

Return on Equity(ttm)

-114.34%

Return on Invested Capital(ttm)

195.85%

Return on Assets(ttm)

-64.58%

Income Statement

Revenue(ttm)

3.94M

Revenue Per Share(ttm)

0.65

Gross Profit(ttm)

3.94M

EBITDA(ttm)³

-88.32M

Net Income Available to Common(ttm)

-131.21M

Diluted EPS(ttm)

-13.32

Share Statistics

Beta (5Y Monthly)

2.45

52-Week Change

-78.21%

S&P 500 52-Week Change

5.05%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

6.11M

Dividend Yield

0.00%

Float⁴

3.27M

% Held by Insiders

8.75%

% Held by Institutions

60.43%

Balance Sheet

Total Cash(mrq)

57.05M

Total Cash Per Share(mrq)

9.33

Total Debt(mrq)

158.00K

Total Debt/Equity(mrq)

-0.55%

Current Ratio(mrq)

2.86%

Quick Ratio(mrq)

3.81%

Book Value Per Share(mrq)

-7.50

Cash Flow

Operating Cash Flow Per Share(ytd)

-12.89

Free Cash Flow(ytd)

-80.87M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ALGS

Aligos Therapeutics, Inc. Common Stock

Aligos Therapeutics, Inc. Common Stock Profile